Literature DB >> 2552175

Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

S R Pollard1, G Dunn, N Cammack, P D Minor, J W Almond.   

Abstract

Infectious cDNAs of the Sabin type 2 poliovirus vaccine virus and a vaccine-derived neurovirulent type 2 strain (P2/117) have been cloned in Escherichia coli. Nucleotide sequence analysis revealed that P2/117 differs from the vaccine strain by just 23 point mutations. Three occur in the 5' noncoding region. The remainder result in a total of 5 coding changes located in VP1, VP4, 2B, and 3D. The likely role of these mutations in the evolution to neurovirulence is discussed.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2552175      PMCID： PMC251143          DOI： 10.1128/JVI.63.11.4949-4951.1989

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  Persistence of immunity after administration of formalin-treated poliovirus vaccine.

Authors:  J E SALK
Journal:  Lancet       Date:  1960-10-01       Impact factor: 79.321

2.  New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence.

Authors:  M A Skinner; V R Racaniello; G Dunn; J Cooper; P D Minor; J W Almond
Journal:  J Mol Biol       Date:  1989-05-20       Impact factor: 5.469

3.  Colony hybridization.

Authors:  M Grunstein; J Wallis
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

5.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

6.  The carrier state in muscular dystrophy of the Duchenne type.

Authors:  A T Milhorat; L Goldstone
Journal:  JAMA       Date:  1965-10-11       Impact factor: 56.272

7.  Mapping of attenuating sequences of an avirulent poliovirus type 2 strain.

Authors:  E G Moss; R E O'Neill; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

9.  Comparative biochemical studies of type 3 poliovirus.

Authors:  P D Minor
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

10.  Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.

Authors:  O M Kew; B K Nottay; M H Hatch; J H Nakano; J F Obijeski
Journal:  J Gen Virol       Date:  1981-10       Impact factor: 3.891
View more
  28 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture.

Authors:  K Matsuura; M Ishikura; H Yoshida; T Nakayama; S Hasegawa; S Ando; H Horie; T Miyamura; T Kitamura
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

3.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

4.  Structure and function analysis of the poliovirus cis-acting replication element (CRE).

Authors:  Ian G Goodfellow; David Kerrigan; David J Evans
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

5.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Molecular identification and analysis of nonserotypeable human enteroviruses.

Authors:  Fei Zhou; Fanrong Kong; Kenneth McPhie; Mala Ratnamohan; Gwendolyn L Gilbert; Dominic E Dwyer
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

7.  Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Authors:  K M Chumakov; L B Powers; K E Noonan; I B Roninson; I S Levenbook
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

8.  Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2.

Authors:  M Equestre; D Genovese; F Cavalieri; L Fiore; R Santoro; R Perez Bercoff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Recognition of picornavirus internal ribosome entry sites within cells; influence of cellular and viral proteins.

Authors:  L O Roberts; R A Seamons; G J Belsham
Journal:  RNA       Date:  1998-05       Impact factor: 4.942

10.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.